<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ICU Admission Prediction in Febrile Oncology Patients - Research Paper</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Crimson+Pro:ital,wght@0,400;0,600;0,700;1,400&family=Inter:wght@400;500;600;700&display=swap');

        :root {
            --primary-color: #1a365d;
            --secondary-color: #2d5a87;
            --accent-color: #3182ce;
            --text-color: #2d3748;
            --light-gray: #f7fafc;
            --border-color: #e2e8f0;
            --success-color: #38a169;
            --warning-color: #d69e2e;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Crimson Pro', Georgia, serif;
            font-size: 18px;
            line-height: 1.8;
            color: var(--text-color);
            background: #fff;
            max-width: 900px;
            margin: 0 auto;
            padding: 40px 60px;
        }

        /* Header Styles */
        .paper-header {
            text-align: center;
            margin-bottom: 40px;
            padding-bottom: 30px;
            border-bottom: 2px solid var(--primary-color);
        }

        .paper-title {
            font-family: 'Inter', sans-serif;
            font-size: 28px;
            font-weight: 700;
            color: var(--primary-color);
            line-height: 1.3;
            margin-bottom: 20px;
        }

        .paper-subtitle {
            font-size: 16px;
            color: #718096;
            font-style: italic;
        }

        .authors {
            font-family: 'Inter', sans-serif;
            font-size: 14px;
            color: #4a5568;
            margin-top: 15px;
        }

        /* Section Styles */
        h1 {
            font-family: 'Inter', sans-serif;
            font-size: 22px;
            font-weight: 700;
            color: var(--primary-color);
            margin: 40px 0 20px 0;
            padding-bottom: 8px;
            border-bottom: 1px solid var(--border-color);
        }

        h2 {
            font-family: 'Inter', sans-serif;
            font-size: 18px;
            font-weight: 600;
            color: var(--secondary-color);
            margin: 30px 0 15px 0;
        }

        h3 {
            font-family: 'Inter', sans-serif;
            font-size: 16px;
            font-weight: 600;
            color: var(--text-color);
            margin: 20px 0 10px 0;
        }

        p {
            margin-bottom: 16px;
            text-align: justify;
        }

        /* Abstract Box */
        .abstract {
            background: linear-gradient(135deg, #f0f5ff 0%, #ebf4ff 100%);
            border-left: 4px solid var(--accent-color);
            padding: 25px 30px;
            margin: 30px 0;
            border-radius: 0 8px 8px 0;
        }

        .abstract h2 {
            margin-top: 0;
            font-size: 16px;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        .abstract p {
            font-size: 16px;
            line-height: 1.7;
        }

        .abstract strong {
            color: var(--primary-color);
        }

        .keywords {
            font-size: 14px;
            color: #4a5568;
            margin-top: 15px;
            font-style: italic;
        }

        /* Tables */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 25px 0;
            font-size: 14px;
            font-family: 'Inter', sans-serif;
        }

        thead {
            background: var(--primary-color);
            color: white;
        }

        th {
            padding: 12px 15px;
            text-align: left;
            font-weight: 600;
            font-size: 13px;
        }

        td {
            padding: 12px 15px;
            border-bottom: 1px solid var(--border-color);
        }

        tbody tr:nth-child(even) {
            background: var(--light-gray);
        }

        tbody tr:hover {
            background: #edf2f7;
        }

        .table-caption {
            font-family: 'Inter', sans-serif;
            font-size: 14px;
            font-weight: 600;
            color: var(--text-color);
            margin-bottom: 10px;
        }

        .highlight-row {
            background: #c6f6d5 !important;
            font-weight: 600;
        }

        /* Figures */
        .figure {
            margin: 35px 0;
            text-align: center;
            page-break-inside: avoid;
        }

        .figure img {
            max-width: 100%;
            height: auto;
            border: 1px solid var(--border-color);
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.05);
        }

        .figure-caption {
            font-family: 'Inter', sans-serif;
            font-size: 14px;
            color: #4a5568;
            margin-top: 12px;
            text-align: center;
        }

        .figure-caption strong {
            color: var(--primary-color);
        }

        .figure-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin: 30px 0;
        }

        .figure-grid .figure {
            margin: 0;
        }

        /* Key Findings Box */
        .key-findings {
            background: linear-gradient(135deg, #f0fff4 0%, #c6f6d5 100%);
            border: 1px solid #9ae6b4;
            border-radius: 8px;
            padding: 25px;
            margin: 30px 0;
        }

        .key-findings h3 {
            color: #22543d;
            margin-top: 0;
        }

        .key-findings ul {
            margin: 15px 0;
            padding-left: 25px;
        }

        .key-findings li {
            margin-bottom: 8px;
            color: #276749;
        }

        /* Warning Box */
        .limitations {
            background: #fffaf0;
            border: 1px solid #fbd38d;
            border-radius: 8px;
            padding: 25px;
            margin: 30px 0;
        }

        .limitations h3 {
            color: #744210;
            margin-top: 0;
        }

        .limitations ul {
            margin: 15px 0;
            padding-left: 25px;
        }

        .limitations li {
            margin-bottom: 8px;
            color: #975a16;
        }

        /* Lists */
        ul,
        ol {
            margin: 15px 0 15px 30px;
        }

        li {
            margin-bottom: 8px;
        }

        /* Metric Cards */
        .metrics-grid {
            display: grid;
            grid-template-columns: repeat(4, 1fr);
            gap: 15px;
            margin: 25px 0;
        }

        .metric-card {
            background: var(--light-gray);
            border-radius: 8px;
            padding: 20px;
            text-align: center;
            border: 1px solid var(--border-color);
        }

        .metric-value {
            font-family: 'Inter', sans-serif;
            font-size: 28px;
            font-weight: 700;
            color: var(--primary-color);
        }

        .metric-label {
            font-family: 'Inter', sans-serif;
            font-size: 12px;
            color: #718096;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-top: 5px;
        }

        .metric-ci {
            font-family: 'Inter', sans-serif;
            font-size: 11px;
            color: #a0aec0;
        }

        /* References */
        .references {
            font-size: 14px;
            line-height: 1.6;
        }

        .references ol {
            padding-left: 25px;
        }

        .references li {
            margin-bottom: 12px;
        }

        /* Footer */
        .paper-footer {
            margin-top: 50px;
            padding-top: 30px;
            border-top: 1px solid var(--border-color);
            font-size: 14px;
            color: #718096;
            text-align: center;
        }

        /* Print Styles */
        @media print {
            body {
                padding: 20px;
                font-size: 12pt;
            }

            .paper-title {
                font-size: 18pt;
            }

            h1 {
                font-size: 14pt;
                page-break-after: avoid;
            }

            h2 {
                font-size: 12pt;
                page-break-after: avoid;
            }

            .figure {
                page-break-inside: avoid;
            }

            .figure img {
                max-width: 90%;
            }

            .metrics-grid {
                grid-template-columns: repeat(4, 1fr);
            }

            table {
                page-break-inside: avoid;
            }
        }

        /* Responsive */
        @media (max-width: 768px) {
            body {
                padding: 20px;
                font-size: 16px;
            }

            .metrics-grid {
                grid-template-columns: repeat(2, 1fr);
            }

            .figure-grid {
                grid-template-columns: 1fr;
            }

            table {
                font-size: 12px;
            }

            th,
            td {
                padding: 8px 10px;
            }
        }
    </style>
</head>

<body>

    <header class="paper-header">
        <h1 class="paper-title">Machine Learning-Based Prediction of ICU Admission in Febrile Oncology Patients: A
            Development and Validation Study</h1>
        <p class="paper-subtitle">Original Research Article</p>
        <p class="authors">[Author names and affiliations to be added]</p>
    </header>

    <section class="abstract">
        <h2>Abstract</h2>
        <p>
            <strong>Background:</strong> Febrile illness in cancer patients can range from self-limiting infections to
            life-threatening sepsis requiring intensive care. Early identification of patients requiring ICU admission
            is crucial for appropriate triage and resource allocation.
        </p>
        <p>
            <strong>Objective:</strong> To develop and validate a machine learning model for predicting ICU admission in
            oncology patients presenting with febrile illness using clinical variables available at initial
            presentation.
        </p>
        <p>
            <strong>Methods:</strong> We conducted a retrospective cohort study of 149 oncology patients presenting with
            febrile illness. An XGBoost classifier was developed and compared to logistic regression and established
            clinical scores (MASCC, qSOFA). Model performance was evaluated using repeated stratified 10×5-fold
            cross-validation with bootstrap confidence intervals.
        </p>
        <p>
            <strong>Results:</strong> Among 149 patients, 81 (54.4%) required ICU admission. The XGBoost model achieved
            an AUROC of 0.934 (95% CI: 0.863-1.000), outperforming logistic regression (0.917), MASCC alone (0.656),
            qSOFA alone (0.838), and combined MASCC+qSOFA (0.864). The model demonstrated good calibration (Brier score:
            0.092) and clinical utility across a range of decision thresholds.
        </p>
        <p>
            <strong>Conclusions:</strong> A machine learning model incorporating routinely available clinical features
            can accurately predict ICU admission in febrile oncology patients, significantly outperforming established
            clinical scores.
        </p>
        <p class="keywords"><strong>Keywords:</strong> machine learning, oncology, febrile neutropenia, ICU admission,
            clinical prediction model, XGBoost</p>
    </section>

    <h1>1. Introduction</h1>

    <p>Febrile illness represents one of the most common oncological emergencies, affecting up to 80% of patients
        receiving chemotherapy for hematologic malignancies and 10-50% of those with solid tumors. While many febrile
        episodes resolve with prompt antimicrobial therapy, a subset of patients rapidly deteriorate and require
        intensive care unit (ICU) admission for hemodynamic support, mechanical ventilation, or management of
        multi-organ dysfunction.</p>

    <p>Early identification of patients at high risk for ICU admission is clinically important for several reasons.
        First, prompt ICU referral in deteriorating patients is associated with improved outcomes. Second, appropriate
        triage optimizes resource utilization in hospitals with limited ICU capacity. Third, risk stratification enables
        tailored monitoring intensity and goals-of-care discussions.</p>

    <p>Several clinical scoring systems have been developed for risk stratification in febrile oncology patients. The
        Multinational Association for Supportive Care in Cancer (MASCC) score identifies low-risk patients suitable for
        outpatient management. The quick Sequential Organ Failure Assessment (qSOFA) identifies patients at risk of poor
        outcomes from sepsis. However, these scores were not specifically designed to predict ICU admission and have
        demonstrated variable performance in this context.</p>

    <p>Machine learning approaches offer the potential to capture complex, non-linear relationships among clinical
        variables and may outperform traditional scoring systems. In this study, we developed and validated a machine
        learning model to predict ICU admission in oncology patients presenting with febrile illness.</p>

    <h1>2. Methods</h1>

    <h2>2.1 Study Design and Population</h2>

    <p>We conducted a retrospective cohort study of consecutive oncology patients presenting with febrile illness.
        Inclusion criteria were: age ≥18 years, active malignancy (solid tumor or hematologic), and presentation with
        fever (temperature ≥38.0°C) or clinical suspicion of infection.</p>

    <h2>2.2 Data Collection</h2>

    <p>Clinical data were extracted from electronic health records including: MASCC score, qSOFA score (0-3),
        hypotension level (none, fluid-responsive, requiring inotropes), tumor type (solid vs. hematologic), metastatic
        status, line of therapy, neutropenia status, infection focus, age group, gender, and comorbidity burden.</p>

    <h2>2.3 Model Development</h2>

    <p>We selected XGBoost (Extreme Gradient Boosting) as the primary machine learning algorithm. Hyperparameters were
        set conservatively (max_depth=3, n_estimators=100, learning_rate=0.1) to prevent overfitting on the small
        dataset. A fixed random seed (42) was used for reproducibility.</p>

    <h2>2.4 Model Validation</h2>

    <p>We employed repeated stratified K-fold cross-validation (10 repeats × 5 folds = 50 total iterations) to obtain
        robust performance estimates. Bootstrap confidence intervals (1000 iterations) were calculated for all metrics.
        A 30% stratified hold-out was used to simulate external validation.</p>

    <h1>3. Results</h1>

    <h2>3.1 Patient Characteristics</h2>

    <p>A total of 149 patients met inclusion criteria. Solid tumors comprised 69.1% (103/149) of the cohort, with 30.9%
        (46/149) having hematologic malignancies. Neutropenia was present in 45.6% (68/149) of patients. The overall ICU
        admission rate was 54.4% (81/149).</p>

    <h2>3.2 Primary Results</h2>

    <div class="metrics-grid">
        <div class="metric-card">
            <div class="metric-value">0.934</div>
            <div class="metric-label">AUROC</div>
            <div class="metric-ci">95% CI: 0.863-1.000</div>
        </div>
        <div class="metric-card">
            <div class="metric-value">0.963</div>
            <div class="metric-label">AUPRC</div>
            <div class="metric-ci">Precision-Recall</div>
        </div>
        <div class="metric-card">
            <div class="metric-value">85.9%</div>
            <div class="metric-label">Accuracy</div>
            <div class="metric-ci">± 6.3%</div>
        </div>
        <div class="metric-card">
            <div class="metric-value">0.092</div>
            <div class="metric-label">Brier Score</div>
            <div class="metric-ci">Calibration</div>
        </div>
    </div>

    <h2>3.3 Model Comparison</h2>

    <p class="table-caption">Table 1. Performance Comparison Across Models</p>
    <table>
        <thead>
            <tr>
                <th>Model</th>
                <th>AUROC (95% CI)</th>
                <th>AUPRC</th>
                <th>Accuracy</th>
                <th>Sensitivity</th>
                <th>Specificity</th>
                <th>Brier</th>
            </tr>
        </thead>
        <tbody>
            <tr class="highlight-row">
                <td><strong>XGBoost (Full)</strong></td>
                <td><strong>0.934 (0.863-1.000)</strong></td>
                <td><strong>0.963</strong></td>
                <td><strong>0.859</strong></td>
                <td>0.877</td>
                <td><strong>0.882</strong></td>
                <td><strong>0.092</strong></td>
            </tr>
            <tr>
                <td>Logistic Regression</td>
                <td>0.917 (0.826-0.994)</td>
                <td>0.947</td>
                <td>0.851</td>
                <td>0.877</td>
                <td>0.809</td>
                <td>0.113</td>
            </tr>
            <tr>
                <td>XGBoost (No Hypotension)</td>
                <td>0.887 (0.771-0.980)</td>
                <td>0.901</td>
                <td>0.812</td>
                <td>0.864</td>
                <td>0.765</td>
                <td>0.131</td>
            </tr>
            <tr>
                <td>MASCC + qSOFA</td>
                <td>0.864 (0.767-0.932)</td>
                <td>0.865</td>
                <td>0.779</td>
                <td>0.963</td>
                <td>0.559</td>
                <td>0.140</td>
            </tr>
            <tr>
                <td>qSOFA Alone</td>
                <td>0.838 (0.733-0.918)</td>
                <td>0.840</td>
                <td>0.710</td>
                <td>0.864</td>
                <td>0.559</td>
                <td>0.152</td>
            </tr>
            <tr>
                <td>MASCC Alone</td>
                <td>0.656 (0.546-0.782)</td>
                <td>0.607</td>
                <td>0.685</td>
                <td>0.988</td>
                <td>0.324</td>
                <td>0.206</td>
            </tr>
        </tbody>
    </table>

    <p>The XGBoost model achieved the highest AUROC (0.934), significantly outperforming MASCC alone (0.656, p<0.001)
            and qSOFA alone (0.838, p=0.02). Performance was comparable to logistic regression (0.917, p=0.32),
            suggesting that the clinical features contain inherently strong signal for this prediction task.</p>

            <h2>3.4 ROC Curve Comparison</h2>

            <div class="figure">
                <img src="figures/fig_roc_comparison.png" alt="ROC Curves Comparison">
                <p class="figure-caption"><strong>Figure 1.</strong> Receiver Operating Characteristic (ROC) curves
                    comparing XGBoost to baseline models. The XGBoost model (AUC = 0.934) outperforms all comparison
                    models including MASCC alone (AUC = 0.656) and qSOFA alone (AUC = 0.838).</p>
            </div>

            <h2>3.5 Feature Importance</h2>

            <div class="figure">
                <img src="figures/fig_feature_importance.png" alt="Feature Importance">
                <p class="figure-caption"><strong>Figure 2.</strong> Feature importance based on XGBoost gain.
                    Hypotension level is the dominant predictor (importance = 0.485), followed by qSOFA score (0.179)
                    and metastatic status (0.071).</p>
            </div>

            <p class="table-caption">Table 2. Top Predictive Features</p>
            <table>
                <thead>
                    <tr>
                        <th>Rank</th>
                        <th>Feature</th>
                        <th>Importance</th>
                        <th>Clinical Interpretation</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>1</td>
                        <td><strong>Hypotension_Level</strong></td>
                        <td>0.485</td>
                        <td>Hemodynamic instability requiring support</td>
                    </tr>
                    <tr>
                        <td>2</td>
                        <td><strong>qSOFA</strong></td>
                        <td>0.179</td>
                        <td>Sepsis severity marker</td>
                    </tr>
                    <tr>
                        <td>3</td>
                        <td>Mets_Binary</td>
                        <td>0.071</td>
                        <td>Metastatic disease burden</td>
                    </tr>
                    <tr>
                        <td>4</td>
                        <td>Comorb</td>
                        <td>0.058</td>
                        <td>Baseline patient vulnerability</td>
                    </tr>
                    <tr>
                        <td>5</td>
                        <td>Focus_PneumResp</td>
                        <td>0.042</td>
                        <td>Respiratory infection focus</td>
                    </tr>
                </tbody>
            </table>

            <h2>3.6 Calibration Assessment</h2>

            <div class="figure">
                <img src="figures/fig_calibration.png" alt="Calibration Curves">
                <p class="figure-caption"><strong>Figure 3.</strong> Calibration curves showing predicted versus
                    observed probabilities. The XGBoost model demonstrates reasonable calibration with a slope of 0.84
                    and Brier score of 0.092. There is slight overconfidence in the mid-probability range.</p>
            </div>

            <p>The XGBoost model demonstrated reasonable calibration with a slope of 0.84 and intercept of -0.16. The
                Brier score was 0.092, indicating good probabilistic accuracy. Calibration curves showed slight
                overconfidence in the mid-probability range.</p>

            <h2>3.7 Decision Curve Analysis</h2>

            <div class="figure">
                <img src="figures/fig_dca.png" alt="Decision Curve Analysis">
                <p class="figure-caption"><strong>Figure 4.</strong> Decision curve analysis showing net benefit across
                    threshold probabilities. The XGBoost model provides positive net benefit compared to "treat all" and
                    "treat none" strategies across threshold probabilities from 10% to 70%, demonstrating clinical
                    utility.</p>
            </div>

            <p>Decision curve analysis demonstrated that the XGBoost model provided positive net benefit across
                threshold probabilities from 10% to 70%, outperforming both the "treat all" and "treat none" strategies
                as well as MASCC and qSOFA alone.</p>

            <h2>3.8 Learning Curve</h2>

            <div class="figure">
                <img src="figures/fig_learning_curve.png" alt="Learning Curve">
                <p class="figure-caption"><strong>Figure 5.</strong> Learning curve showing model performance as a
                    function of training set size. The model approaches asymptotic performance around n=100 samples,
                    with the gap between training and validation scores narrowing as sample size increases.</p>
            </div>

            <h2>3.9 Subgroup Analysis</h2>

            <p class="table-caption">Table 3. Performance Across Patient Subgroups</p>
            <table>
                <thead>
                    <tr>
                        <th>Subgroup</th>
                        <th>N</th>
                        <th>ICU Events</th>
                        <th>AUROC (95% CI)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Solid Tumors</td>
                        <td>103</td>
                        <td>56</td>
                        <td>0.941 (0.890-0.983)</td>
                    </tr>
                    <tr>
                        <td>Hematologic Malignancies</td>
                        <td>46</td>
                        <td>25</td>
                        <td>0.941 (0.851-0.998)</td>
                    </tr>
                    <tr>
                        <td>With Neutropenia</td>
                        <td>68</td>
                        <td>34</td>
                        <td>0.941 (0.857-0.997)</td>
                    </tr>
                    <tr>
                        <td>Without Neutropenia</td>
                        <td>81</td>
                        <td>47</td>
                        <td>0.937 (0.882-0.983)</td>
                    </tr>
                </tbody>
            </table>

            <p>Model performance was consistent across tumor type and neutropenia status. Performance in the youngest
                age group showed wider confidence intervals due to small sample size.</p>

            <h2>3.10 Simulated External Validation</h2>

            <p>On the 30% held-out validation set (n=45, 24 ICU admissions), the model achieved AUROC of 0.933 (95% CI:
                0.846-0.986), accuracy of 0.800, sensitivity of 0.792, and specificity of 0.810. Performance was
                consistent with internal cross-validation estimates.</p>

            <h2>3.11 Threshold Optimization</h2>

            <p class="table-caption">Table 4. Performance at Different Probability Thresholds</p>
            <table>
                <thead>
                    <tr>
                        <th>Threshold</th>
                        <th>Sensitivity</th>
                        <th>Specificity</th>
                        <th>PPV</th>
                        <th>NPV</th>
                        <th>Youden Index</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>0.30</td>
                        <td>0.901</td>
                        <td>0.765</td>
                        <td>0.820</td>
                        <td>0.867</td>
                        <td>0.666</td>
                    </tr>
                    <tr>
                        <td>0.40</td>
                        <td>0.889</td>
                        <td>0.853</td>
                        <td>0.878</td>
                        <td>0.866</td>
                        <td>0.742</td>
                    </tr>
                    <tr>
                        <td><strong>0.50</strong></td>
                        <td><strong>0.877</strong></td>
                        <td><strong>0.882</strong></td>
                        <td><strong>0.899</strong></td>
                        <td><strong>0.857</strong></td>
                        <td><strong>0.759</strong></td>
                    </tr>
                    <tr>
                        <td>0.60</td>
                        <td>0.864</td>
                        <td>0.912</td>
                        <td>0.921</td>
                        <td>0.849</td>
                        <td>0.776</td>
                    </tr>
                    <tr>
                        <td>0.70</td>
                        <td>0.840</td>
                        <td>0.926</td>
                        <td>0.932</td>
                        <td>0.829</td>
                        <td>0.766</td>
                    </tr>
                </tbody>
            </table>

            <p>The optimal threshold by Youden index was 0.85, balancing sensitivity and specificity. For clinical
                applications prioritizing sensitivity (avoiding missed ICU admissions), a lower threshold of 0.30-0.40
                may be preferred.</p>

            <div class="key-findings">
                <h3>✅ Key Findings</h3>
                <ul>
                    <li><strong>AUROC 0.934</strong> — Excellent discrimination, significantly outperforming established
                        scores</li>
                    <li><strong>Hypotension</strong> is the dominant predictor, followed by qSOFA score</li>
                    <li><strong>Consistent performance</strong> across tumor types and neutropenia status</li>
                    <li><strong>Good calibration</strong> (Brier score 0.092, slope 0.84)</li>
                    <li><strong>Clinical utility</strong> demonstrated across threshold probabilities 10-70%</li>
                </ul>
            </div>

            <h1>4. Discussion</h1>

            <h2>4.1 Principal Findings</h2>

            <p>We developed and validated a machine learning model for predicting ICU admission in febrile oncology
                patients that achieved excellent discriminative ability (AUROC 0.934). The model significantly
                outperformed established clinical scores including MASCC (AUROC 0.656) and qSOFA (AUROC 0.838).
                Performance was robust across validation approaches and patient subgroups.</p>

            <h2>4.2 Clinical Implications</h2>

            <p><strong>Role of Hypotension:</strong> The finding that 100% of patients requiring inotropic support
                (Hypotension Level 2) were admitted to ICU reflects standard clinical practice—patients with refractory
                hypotension require ICU-level care. This represents a clinical protocol rather than a prediction, but
                the model still adds value by integrating this information with other risk factors for patients without
                clear hemodynamic instability.</p>

            <p><strong>Decision Support:</strong> The model may be most useful for patients in the "intermediate risk"
                category—those without obvious ICU-level decompensation but with elevated risk based on other features.
            </p>

            <div class="limitations">
                <h3>⚠️ Limitations</h3>
                <ul>
                    <li><strong>Sample size (n=149)</strong> — Limited power to detect small performance differences
                    </li>
                    <li><strong>Single-center data</strong> — External validation at independent sites is essential</li>
                    <li><strong>Retrospective design</strong> — Prospective validation needed</li>
                    <li><strong>Hypotension circularity</strong> — Strong predictor may reflect clinical protocol</li>
                    <li><strong>No biomarkers</strong> — Laboratory values (lactate, procalcitonin) not included</li>
                </ul>
            </div>

            <h1>5. Conclusions</h1>

            <p>A machine learning model incorporating routinely available clinical features can accurately predict ICU
                admission in oncology patients presenting with febrile illness, significantly outperforming established
                clinical scores. Hypotension status and qSOFA are the most important predictors. The model demonstrates
                consistent performance across patient subgroups and shows clinical utility on decision curve analysis.
                <strong>Prospective external validation is required before clinical implementation.</strong></p>

            <h1>References</h1>

            <div class="references">
                <ol>
                    <li>Klastersky J, et al. The Multinational Association for Supportive Care in Cancer risk index.
                        <em>J Clin Oncol</em>. 2000;18(16):3038-51.</li>
                    <li>Kuderer NM, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult
                        cancer patients. <em>Cancer</em>. 2006;106(10):2258-66.</li>
                    <li>Young MP, et al. Inpatient transfers to the intensive care unit: delays are associated with
                        increased mortality. <em>J Gen Intern Med</em>. 2003;18(2):77-83.</li>
                    <li>Teh BW, et al. Risk stratification of fever and neutropenia episodes in hematology−oncology
                        patients. <em>Support Care Cancer</em>. 2018;26(11):3725-32.</li>
                    <li>Klastersky J, Paesmans M. The MASCC risk index score: 10 years of use for identifying low-risk
                        febrile neutropenic cancer patients. <em>Support Care Cancer</em>. 2013;21(5):1487-95.</li>
                    <li>Seymour CW, et al. Assessment of clinical criteria for sepsis (Sepsis-3). <em>JAMA</em>.
                        2016;315(8):762-74.</li>
                    <li>Kaukonen KM, et al. Mortality related to severe sepsis and septic shock among critically ill
                        patients in Australia and New Zealand. <em>JAMA</em>. 2014;311(13):1308-16.</li>
                    <li>Rajkomar A, et al. Machine learning in medicine. <em>N Engl J Med</em>. 2019;380(14):1347-58.
                    </li>
                    <li>Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. <em>KDD '16</em>. 2016;785-94.
                    </li>
                    <li>Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models.
                        <em>Med Decis Making</em>. 2006;26(6):565-74.</li>
                </ol>
            </div>

            <footer class="paper-footer">
                <p><strong>Data Availability:</strong> The de-identified dataset is available upon reasonable request.
                </p>
                <p><strong>Code Availability:</strong> Analysis code available at [GitHub repository]</p>
                <p><strong>Conflicts of Interest:</strong> The authors declare no conflicts of interest.</p>
                <p style="margin-top: 20px; color: #a0aec0;">Report generated: January 4, 2026 | Analysis: XGBoost with
                    10×5-fold stratified CV | Random seed: 42</p>
            </footer>

</body>

</html>